Vepdegestrant Mechanism of Action: The First PROTAC for Breast Cancer Explained

The FDA just approved the first-ever PROTAC drug — and it's changing how we treat breast cancer. Vepdegestrant (brand name Veppanu) received FDA approval on May 1st, 2026, for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. But what makes this drug genuinely different isn't just the approval — it's the mechanism. Instead of blocking the estrogen receptor, vepdegestrant destroys it entirely, using the cancer cell's own protein disposal system against itself. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. https://www.fda.gov/drugs/resources-i... 2. https://medical.lilly.com/us/diseases... 3. https://www.globenewswire.com/news-re... 4. https://ir.arvinas.com/news-releases/... 5. Campone, M., De Laurentiis, M., Jhaveri, K., Hu, X., Ladoire, S., Patsouris, A., Zamagni, C., Cui, J., Cazzaniga, M., Cil, T., Jerzak, K. J., Fuentes, C., Yoshinami, T., Rodriguez-Lescure, A., Sezer, A., Fontana, A., Guarneri, V., Molckovsky, A., Mouret-Reynier, M. A., Demirci, U., … VERITAC-2 Study Group (2025). Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. The New England journal of medicine, 393(6), 556–568. https://doi.org/10.1056/NEJMoa2505725 6. https://www.pfizeroncologydevelopment... 7. Hamilton, E. P., Ma, C., De Laurentiis, M., Iwata, H., Hurvitz, S. A., Wander, S. A., Danso, M., Lu, D. R., Perkins Smith, J., Liu, Y., Tran, L., Anderson, S., & Campone, M. (2024). VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England), 20(32), 2447–2455. https://doi.org/10.1080/14796694.2024... #BreastCancer #Vepdegestrant #PROTAC #CancerTreatment #OncologyUpdate #BreastCancerResearch #ESR1Mutation #CancerPharmacology #FDA2026 #FDAApproval #MetastaticBreastCancer #ERPositiveBreastCancer #CancerScience #Fulvestrant #VERITAC2 #DrugMechanism #CancerDrug #Pharmacology #MedicalEducation #OncologyNews #TargetedTherapy #ProteinDegradation #CancerBiology #NewCancerDrug #BreastCancerAwareness #MedEd #ClinicalTrials #CancerResearch #Veppanu #PROTACdrug